# Migraine prophylaxis treatment studies

> Live situation record from CLSTR: https://clstr.news/situations/migraine-prophylaxis-treatment-studies
> Updated: 2026-08-03T13:40:06.000Z. Sources: 2. Developments: 2.

In early July 2026, researchers at Bellvitge Hospital reported that the oral CGRP receptor antagonist atogepant significantly reduced migraine attack frequency in patients whose condition was refractory to other therapies.

By early August 2026, a larger prospective study of 90 migraine patients in Germany showed that preventive treatments—including CGRP‑targeted monoclonal antibodies, botulinum toxin, and oral agents such as topiramate and atogepant—were associated with measurable improvements in cognitive performance, particularly executive function, during headache‑free periods. The cognitive gains correlated with reductions in monthly moderate‑to‑severe headache days, confirming the efficacy and tolerability of these prophylactic options.

## Timeline

### 2026-08-03: Migraine Prophylaxis Improves Cognition and Shows Drug Efficacy

Studies show CGRP antibodies or botulinum toxin improve cognition in migraine patients, while a comparison of topiramate and atogepant confirms both as effective oral preventives.

2 sources. https://clstr.news/cluster/migraine-prophylaxis-improves-cognition-and-shows-drug-efficacy

### 2026-07-08: Bellvitge Hospital study finds atogepant cuts migraine attacks in refractory patients

A Spanish multicenter study of 252 refractory migraine patients found atogepant reduced migraine days by ≥50% in 30% and improved symptoms in 44%, offering a new option for those unresponsive to existingPrevent

3 sources. https://clstr.news/cluster/bellvitge-hospital-study-finds-atogepant-cuts-migraine-attacks-in-refractory-patients

---
Cite as: Migraine prophylaxis treatment studies. CLSTR, https://clstr.news/situations/migraine-prophylaxis-treatment-studies